Julie Rempe, PA
Physician Assistant · York, NENPI 1740234194
Payments from drug & device makers
Across 221 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$443
- Astellas Pharma US Inc$297
- Amgen$258
- Johnson & Johnson$115
- Lilly USA, LLC$101
- plus $785 from 29 others
What the payments were for
- Food & beverage$3,35497%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,445 |
| Novo Nordisk | 28 | $443 |
| Astellas Pharma US Inc | 8 | $297 |
| Amgen | 20 | $258 |
| Johnson & Johnson | 6 | $115 |
| Lilly USA, LLC | 7 | $101 |
| Bayer | 6 | $80 |
| Organon | 6 | $66 |
| GSK | 4 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Merck | 3 | $44 |
| Boehringer Ingelheim | 3 | $44 |
| Exact Sciences | 3 | $42 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Itamar Medical Inc | 1 | $28 |
| Vertex | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| CSL Behring | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Biogen | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,444 in reported general payments places this provider in the 90th percentile of 1,127 physician assistant providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $199,445 |
| EliquisApixaban | 98 | $71,273 |
| OzempicSemaglutide | 51 | $46,529 |
| XareltoRivaroxaban | 88 | $43,240 |
| TrulicityDulaglutide | 42 | $41,941 |
| RybelsusSemaglutide | 33 | $39,215 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $35,712 |
| MounjaroTirzepatide | 31 | $32,441 |
| VraylarCariprazine Hcl | 20 | $32,023 |
| TradjentaLinagliptin | 21 | $17,126 |
| FarxigaDapagliflozin Propanediol | 23 | $16,608 |
| LyricaPregabalin | 13 | $15,474 |
| PremarinEstrogens, Conjugated | 48 | $13,050 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,373 |
| Bydureon BciseExenatide Microspheres | 11 | $9,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $443 | $85,74484 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $101 | $74,38273 claims |
| GSKTrelegy Ellipta, Shingrix, Incruse Ellipta | $52 | $45,99886 claims |
| Johnson & JohnsonXarelto | $115 | $43,24088 claims |
| Boehringer IngelheimTradjenta, Spiriva Respimat, Jardiance | $44 | $36,20146 claims |
| AbbVieVraylar | $1,445 | $32,02320 claims |
| MerckJanuvia | $44 | $7,20811 claims |
| Eisai Inc.Dayvigo | $16 | $4,19413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,127 physician assistant providers in Nebraska.
Other physician assistant in York
- Kimberly GatesOmaha$109K
- Kandice DoleshOmaha$106K
- Ronda FoleyElkhorn$64K
- Kathryn KestiOmaha$34K
- Sarah GretemanOmaha$24K
- Joel JasaGrand Island$18K
- Christopher BeasleyOmaha$15K
- Laura TvrdyLincoln$13K
- Courtney MaresLincoln$13K
- Corrine GiggeeOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.